Altered fibrin clot structure/function in patients with antiphospholipid syndrome: Association with thrombotic manifestation

Thrombosis and Haemostasis

Volumn 112, Issue 2, 2014, Pages 287-296

  Celińska Löwenhoff, Magdalena ^a   Iwaniec, Teresa ^a   Padjas, Agnieszka ^a   Musiał, Jacek ^a   Undas, Anetta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antiphospholipid syndrome; Fibrinolysis; Plasma fibrin clot structure

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; D DIMER; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRIN CLOT; FIBRIN CLOT PERMEABILITY; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERMEABILITY; PHENOTYPE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TURBIDITY; VENOUS THROMBOEMBOLISM; BLOOD; BLOOD CLOTTING TEST; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPLICATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; POLAND; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; STATISTICAL MODEL; STROKE; TIME; ULTRASTRUCTURE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; LINEAR MODELS; MALE; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; POLAND; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; STROKE; THROMBOSIS; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84905195499     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-11-0980     Document Type: Article

References (44)

1. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368: 1033-1044.
2. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376: 1498-1509.
3. Rodrigues CE, Carvalho JF, Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest 2010; 40: 350-359.
4. Arnson Y, Shoenfeld Y, Alon E, et al. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum 2010; 40: 97-108.
5. Soltész P, Szekanecz Z, Kiss E, et al. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev 2007; 6: 379-386.
6. Marchetti T, Cohen M, Gris JC, et al. Diagnosis and management of obstetrical antiphospholipid syndrome: where do we stand? Pol Arch Med Wewn 2013; 123: 713-720.
7. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
8. Musial J, Swadzba J, Motyl A, et al. Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis. J Rheumatol 2003; 30: 723-730.
9. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118: 4714-4718.
10. Vega-Ostertag ME, Pierangeli SS. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. Curr Rheumatol Rep 2007; 9: 190-197.
11. Musiał J, Swadzba J, Jankowski M, et al. Thrombin generation measured ex vivo following microvascular injury is increased in SLE patients with antiphospholipid-protein antibodies. Thromb Haemost 1997; 78: 1173-1177.
12. Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12: 53-57.
13. Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004; 136: 393-401.
14. Undas A, Ariëns RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88-99.
15. Undas A. Acquired dysfibrinogenemia in atherosclerotic vascular disease. Pol Arch Med Wewn 2011; 121: 110-119.
16. Undas A, Szuldrzynski K, Stepien E, et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2007; 196: 551-558.
17. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
18. Undas A, Podolec P, Zawilska K, et al. Altered fibrin clot structure/function as a novel risk factor for cryptogenic ischaemic stroke. Stroke. 2009; 40: 1499-1501.
19. Okraska-Bylica A, Wilkosz T, Słowik L, et al. Altered fibrin clot properties in patients with premature peripheral artery disease. Pol Arch Med Wewn 2012; 122: 608-615.
20. Undas A, Zawilska K, Ciesla-Dul M, et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-4278.
21. Zolcinski M, Ciesla-Dul M, Undas A. Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism. Thromb Haemost 2012; 107: 1180-1182.
22. Sciascia S, Roccatello D, Bertero MT, et al. 8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. Inflamm Res 2012; 61: 809-816.
23. Kwasny-Krochin B, Gluszko P, Undas A. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis. Thromb Res 2010; 126: 11-16.
24. Bertsias G, Carvera R, Boumpas TD. Systemic lupus erythematosus: pathogenesis and clinical features. In: Bijlsma JWJ eds. EULAR Textbook of Rheumatic Diseases. 1st ed. London BMJ Group 2012; pp. 476-505.
25. Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 2011; 270: 110-122.
26. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737-1740.
27. Mills JD, Ariens RA, Mansfield MW, et al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942.
28. Blombäck B, Carlsson K, Hessel B, et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
29. Pankiw-Bembenek O, Zalewski J, Goralczyk T, et al. A history of early stent thrombosis is associated with prolonged clot lysis time. Thromb Haemost 2012; 107: 513-520.
30. de la Red G, Tassies D, Espinosa G, et al. Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels. Thromb Haemost 2009; 101: 312-316.
31. Gajos G, Zalewski J, Rostoff P, et al. Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). Arterioscler Thromb Vasc Biol 2011; 31: 1696-1702.
32. Boehm TK, DeNardin E. Fibrinogen binds IgG antibody and enhances IgG-mediated phagocytosis. Hum Antibodies 2008; 17: 45-56.
33. Talens S, Leebeek FWG, Demmers JAA, et al. Identification of fibrin clot-bound plasma proteins. PLoS ONE 2012; 7: e41966.
34. Undas A, Celinska-Löwenhoff M, Löwenhoff T, et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4: 1029-1036.
35. Yasuda S, Atsumi T, Ieko M, et al. Nicked beta2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004; 103: 3766-3772.
36. Bu C, Gao L, Xie W, et al. Beta2-glycoprotein I is a cofactor for tissue plasminogen activator-mediated plasminogen activation. Arthritis Rheum 2009; 60: 559-568.
37. Ieko M, Yoshida M, Naito S, et al. Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation. Int J Hematol 2010; 91: 776-783.
38. Yang CD, Hwang KK, Yan W, et al. Identification of anti-plasmin antiobodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004; 172: 5765-5773.
39. Chen PP, Yang CD, Ede K, et al. Some antiphospholipid antibodies bind to hemostasis and fibrinolysis proteases and promote thrombosis. Lupus 2008; 17: 916-921.
40. Cugno M, Cabibbe M, Galli M, et al. Antibodies to tissue-type plasminogen activator (t-PA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of t-PA in 2 patients. Blood 2004; 103: 2121-2126.
41. Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-121.
42. Fatah K, Silveira A, Tornval P, et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540.
43. Ajjan RA, Standeven KF, Khanbhai M, et al. Effects of aspirin on clot structure and fibrinolysis using a novel cellular system. Arterioscler Thromb Vasc Biol 2009; 29: 712-717.
44. Standeven KF, Uitte de Willige S, Carter AM, et al. Heritability of clot formation. Semin Thromb Haemost 2009; 35: 458-467.